LAURA Trial (NEJM/ASCO 2024): Osimertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

30 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Discover the game-changing results of the LAURA trial, a pivotal Phase III study evaluating osimertinib as consolidation therapy following definitive chemoradiotherapy in patients with Stage III EGFR-mutated non-small cell lung cancer (NSCLC).

Presented at ASCO 2024 and published in the New England Journal of Medicine (NEJM, 2024), this study explores whether targeted therapy can delay progression and improve survival in this historically underserved population.

Targeted Therapy | EGFR | NSCLC | Stage III | Osimertinib | Lung Cancer | Consolidation Therapy

#LAURATrial #Osimertinib #EGFR #NSCLC #StageIIILungCancer #ASCO2024 #NEJM2024 #TargetedTherapy #LungCancerResearch #ClinicalTrials #Oncology
Categoria
Oncology
Commenta per primo questo video.

Prossimo